<DOC>
	<DOCNO>NCT02719574</DOCNO>
	<brief_summary>This Phase 1/1b study utilize multicenter , open-label dose-escalation design evaluate safety , PK , PD FT-2102 ( single agent ) FT-2102 + azacitidine ( combination agent ) administer via one intermittent dose schedule . Approximately 48 patient enrol dose-escalation portion study one schedule follow approximately 14 patient expansion cohort</brief_summary>
	<brief_title>Dose-Escalation Study FT-2102 Single Agent Combination With Azacitidine Patients With AML MDS With IDH1 Mutation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Pathologically proven acute myeloid leukemia high risk high risk MDS define World Health Organization ( WHO ) criterion Revised International Prognostic Scoring System ( IPSSR ) either relapsed refractory standard therapy , standard treatment contraindicate . Patients must document IDH1R132 genemutated disease evaluate site Good kidney liver function No prior organ allograft For fertile men woman , agreement use effective contraceptive method duration study participation 90 day Previously treat prior IDH1 target therapy History prior malignancy unless disease free &gt; 2 year . Patients symptomatic central nervous system ( CNS ) metastases tumor location ( spinal cord compression , compressive mass , uncontrolled painful lesion , bone fracture , etc . ) necessitate urgent therapeutic intervention , palliative care , surgery radiation therapy Treatment major surgery ( require general anesthesia ) within one month prior study entry Patients unable swallow oral medication , patient gastrointestinal condition ( e.g . malabsorption , gastric small bowel resection , etc . ) deem jeopardize intestinal absorption Congestive heart failure ( New York Heart Association Class III IV ) unstable angina pectoris . Previous history myocardial infarction within 1 year prior study entry , uncontrolled hypertension uncontrolled arrhythmias Pulmonary disease ( e.g . COPD , asthma , etc ) control ( moderate severe symptom ) current medication Known HIV positivity Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>IDH1</keyword>
	<keyword>IDH</keyword>
</DOC>